Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect
26
Issued Date
2025-01-01
Resource Type
ISSN
13960296
eISSN
15298019
Scopus ID
2-s2.0-105001578480
Journal Title
Dermatologic Therapy
Volume
2025
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatologic Therapy Vol.2025 No.1 (2025)
Suggested Citation
Thanasarnaksorn W., Supasiri T., Panich U., Thanachaiphiwat S., Salakshna N. Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect. Dermatologic Therapy Vol.2025 No.1 (2025). doi:10.1155/dth/5550483 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109362
Title
Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Melasma is a challenging hyperpigmentation disorder without absolute treatment. Aims: This study aimed to evaluate the effects of intradermal botulinum toxin A (BoNT-A) on melasma and the protective effects of BoNT-A on UVA-induced melanogenesis in B16F10 melanoma cells. Patients/Methods: This study is a split-face randomized, double-blind, placebo-controlled trial in 12 melasma patients who received intradermal abobotulinumtoxinA injection into melasma lesions. An in vitro study was also conducted in B16F10 melanoma cells treated with different concentrations of BoNT-A prior to exposure to UVA. Cell viability and cellular melanogenesis were determined. Results: The adjusted MASI scores on the BoNT-A side were significantly lower than the control at 3 months after injection, 2.8 versus 4.5 (p < 0.001), respectively. BoNT-A injection significantly reduced the MASI score at 2 and 3 months compared with the baseline of 4.1–3.2 (22%) (p < 0.001) and 2.8 (31.7%) (p < 0.001), respectively. Melanin content and tyrosinase activity in B16F10 cells with or without UVA irradiation were significantly reduced by treatment with BoNT-A in a dose-dependent manner without causing cytotoxicity. Conclusions: BoNT-A has a potentially beneficial effect in the treatment of melasma due to its antimelanogenic effect. Trial Registration: Clinical Trial Registry identifier: TCTR20250118001.